Physician profile
Kenneth Ramey
NPI 1023061975
$682.23
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $299 · 2021: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $140.68 | 2019-2020 | |
| Daiichi Sankyo INC. | $125.00 | 2019 | |
| Amgen INC. | $124.43 | 2020 | |
| Alkermes, INC. | $123.98 | 2021 | |
| Sanofi Pasteur INC. | $52.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.50 | 2019 | |
| Abbvie INC. | $18.83 | 2020 | |
| Hikma Pharmaceuticals USA | $18.13 | 2020 | |
| Hologic Sales and Service, LLC | $12.56 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ramey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.